# Augmenting Cerebral Blood Flow to Treat Established Multiple Sclerosis

> **NCT02466074** · PHASE2 · TERMINATED · sponsor: **The University of Texas Health Science Center, Houston** · enrollment: 5 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Acetazolamide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02466074
- **Lead sponsor:** The University of Texas Health Science Center, Houston
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-08-17
- **Primary completion:** 2022-02-07
- **Final completion:** 2022-02-07
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Inadequate recruitment; termination of funding
- **Last updated:** 2023-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02466074

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02466074, "Augmenting Cerebral Blood Flow to Treat Established Multiple Sclerosis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02466074. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*